The drugs target both the cells and the virus, blocking multiple key steps of the viral life cycle. Our current formulations have shown remarkable efficacy in preventing SARS-CoV-2 lung infection and lung tissue damage in mouse models. Our research team has access to biosafety level 3 facilities, clinical virus isolates, including SARS-COV-2 and all its known variants of concerns, and a large network of collaborators in academia, local hospitals and industry.
We aim at developing a cost effective, safe, and easy to use antiviral therapy to prevent and facilitate recovery from respiratory infections caused by multiple human pathogenic viruses.